876343-10-1

Basic information

• Product Name: 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine;4-Chloro-6-iodo-7H-pyrrol...;4-chloro-6-iodo-7H-pyrrolo[2;4-chloro-6-iodo-1H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 876343-10-1
• Molecular Formula: C₆H₃ClIN₃
• Molecular Weight: 279.47
• Product Categories: CHIRAL CHEMICALS;pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 876343-10-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 2.284 g/cm³
• Refractive Index: 1.804
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.74±0.50(Predicted)
• CAS DataBase Reference: 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine(876343-10-1)
• EPA Substance Registry System: 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine(876343-10-1)

Safety Data

• Hazardous Substances Data: 876343-10-1(Hazardous Substances Data)

Usage

General Description

4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound with the molecular formula C6H3ClIN3. It is a heterocyclic aromatic compound containing both chlorine and iodine atoms, as well as a pyrrolopyrimidine ring system. 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals due to its versatile reactivity and structural properties. Additionally, it has been studied for its potential biological activities, including as an anti-cancer agent and as a ligand for metal-catalyzed reactions. Its unique structure and properties make it a valuable tool in the development of new chemical compounds for various applications.

InChI:InChI=1/C6H3ClIN3/c7-5-3-1-4(8)11-6(3)10-2-9-5/h1-2H,(H,9,10,11)

Upstream product

• 3680-71-5 7-deazahypoxanthine 
• 186519-89-1 7-(benzenesulfonyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 3680-71-5 Allopurinol 
• 876343-09-8 7-(benzenesulfonyl)-4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1637437-41-2 C₁₄H₁₂FIN₄O 
• 1637438-20-0 C₂₁H₂₀N₄O 
• 1637438-32-4 C₂₀H₁₈N₄O 
• 1637438-64-2 C₂₀H₁₈N₄O 
• 1637569-24-4 C₂₁H₂₀N₄O 
• 497841-30-2 {3-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanol 
• 497841-27-7 {4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanol 
• 1637437-71-8 (R)-3-methoxy-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzaldehyde 
• 1637437-39-8 (R)-(3-methoxy-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methanol 
• 1637438-12-0 (S)-2-((6-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol 
• 1637437-61-6 (S)-2-((6-(4-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol 
• 1637438-04-0 (S)-4-(4-((2-hydroxy-1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methoxybenzaldehyde 
• 1637437-96-7 (S)-2-((6-(4-(hydroxymethyl)-2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol 
• 1643962-37-1 (R)-6-iodo-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

4-AMINO-6-ARYL[2,3-D]PYRIMIDINES FOR THE INHIBITION OF EGFR TYROSINE KINASE

This invention relates to certain new pyrrolo-, thieno-, and furo-[2,3- d]pyrimidine compounds, such as of general formula (I) These compounds are epidermal growth factor receptor tyrosine kinase inhibitors and therefore offer potential in the treatment of cancer.

ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS

Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mekl, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2